138 related articles for article (PubMed ID: 28916223)
21. Dysregulation of BET proteins in levodopa-induced dyskinesia.
A Figge D; Standaert DG
Neurobiol Dis; 2017 Jun; 102():125-132. PubMed ID: 28286180
[TBL] [Abstract][Full Text] [Related]
22. Histone modifications underlie monocyte dysregulation in patients with systemic sclerosis, underlining the treatment potential of epigenetic targeting.
van der Kroef M; Castellucci M; Mokry M; Cossu M; Garonzi M; Bossini-Castillo LM; Chouri E; Wichers CGK; Beretta L; Trombetta E; Silva-Cardoso S; Vazirpanah N; Carvalheiro T; Angiolilli C; Bekker CPJ; Affandi AJ; Reedquist KA; Bonte-Mineur F; Zirkzee EJM; Bazzoni F; Radstake TRDJ; Rossato M
Ann Rheum Dis; 2019 Apr; 78(4):529-538. PubMed ID: 30793699
[TBL] [Abstract][Full Text] [Related]
23. The epigenetic regulator BRD4 is required for myofibroblast differentiation of knee fibroblasts.
Dudakovic A; Bayram B; Bettencourt JW; Limberg AK; Galvan ML; Carrasco ME; Stans B; Thaler R; Morrey ME; Sanchez-Sotelo J; Berry DJ; van Wijnen AJ; Abdel MP
J Cell Biochem; 2023 Feb; 124(2):320-334. PubMed ID: 36648754
[TBL] [Abstract][Full Text] [Related]
24. BET Inhibition Upregulates SIRT1 and Alleviates Inflammatory Responses.
Kokkola T; Suuronen T; Pesonen M; Filippakopoulos P; Salminen A; Jarho EM; Lahtela-Kakkonen M
Chembiochem; 2015 Sep; 16(14):1997-2001. PubMed ID: 26212199
[TBL] [Abstract][Full Text] [Related]
25. Nanog requires BRD4 to maintain murine embryonic stem cell pluripotency and is suppressed by bromodomain inhibitor JQ1 together with Lefty1.
Horne GA; Stewart HJ; Dickson J; Knapp S; Ramsahoye B; Chevassut T
Stem Cells Dev; 2015 Apr; 24(7):879-91. PubMed ID: 25393219
[TBL] [Abstract][Full Text] [Related]
26. Epigenetics in radiation-induced fibrosis.
Weigel C; Schmezer P; Plass C; Popanda O
Oncogene; 2015 Apr; 34(17):2145-55. PubMed ID: 24909163
[TBL] [Abstract][Full Text] [Related]
27. BET Bromodomain Blockade Mitigates Intimal Hyperplasia in Rat Carotid Arteries.
Wang B; Zhang M; Takayama T; Shi X; Roenneburg DA; Kent KC; Guo LW
EBioMedicine; 2015 Nov; 2(11):1650-61. PubMed ID: 26870791
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of BET proteins impairs estrogen-mediated growth and transcription in breast cancers by pausing RNA polymerase advancement.
Sengupta S; Biarnes MC; Clarke R; Jordan VC
Breast Cancer Res Treat; 2015 Apr; 150(2):265-78. PubMed ID: 25721606
[TBL] [Abstract][Full Text] [Related]
29. Resistance to Epigenetic-Targeted Therapy Engenders Tumor Cell Vulnerabilities Associated with Enhancer Remodeling.
Iniguez AB; Alexe G; Wang EJ; Roti G; Patel S; Chen L; Kitara S; Conway A; Robichaud AL; Stolte B; Bandopadhayay P; Goodale A; Pantel S; Lee Y; Cheff DM; Hall MD; Guha R; Davis MI; Menard M; Nasholm N; Weiss WA; Qi J; Beroukhim R; Piccioni F; Johannessen C; Stegmaier K
Cancer Cell; 2018 Dec; 34(6):922-938.e7. PubMed ID: 30537514
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of Super-Enhancer Activity in Autoinflammatory Site-Derived T Cells Reduces Disease-Associated Gene Expression.
Peeters JG; Vervoort SJ; Tan SC; Mijnheer G; de Roock S; Vastert SJ; Nieuwenhuis EE; van Wijk F; Prakken BJ; Creyghton MP; Coffer PJ; Mokry M; van Loosdregt J
Cell Rep; 2015 Sep; 12(12):1986-96. PubMed ID: 26387944
[TBL] [Abstract][Full Text] [Related]
31. BET Bromodomain Inhibition as a Therapeutic Strategy in Ovarian Cancer by Downregulating FoxM1.
Zhang Z; Ma P; Jing Y; Yan Y; Cai MC; Zhang M; Zhang S; Peng H; Ji ZL; Di W; Gu Z; Gao WQ; Zhuang G
Theranostics; 2016; 6(2):219-30. PubMed ID: 26877780
[TBL] [Abstract][Full Text] [Related]
32. Enhancer Architecture and Essential Core Regulatory Circuitry of Chronic Lymphocytic Leukemia.
Ott CJ; Federation AJ; Schwartz LS; Kasar S; Klitgaard JL; Lenci R; Li Q; Lawlor M; Fernandes SM; Souza A; Polaski D; Gadi D; Freedman ML; Brown JR; Bradner JE
Cancer Cell; 2018 Dec; 34(6):982-995.e7. PubMed ID: 30503705
[TBL] [Abstract][Full Text] [Related]
33. BET Bromodomain as a Target of Epigenetic Therapy.
Noguchi-Yachide T
Chem Pharm Bull (Tokyo); 2016; 64(6):540-7. PubMed ID: 27250788
[TBL] [Abstract][Full Text] [Related]
34. Compensatory RNA polymerase 2 loading determines the efficacy and transcriptional selectivity of JQ1 in Myc-driven tumors.
Donato E; Croci O; Sabò A; Muller H; Morelli MJ; Pelizzola M; Campaner S
Leukemia; 2017 Feb; 31(2):479-490. PubMed ID: 27443262
[TBL] [Abstract][Full Text] [Related]
35. Epigenetic Therapy for the Treatment of Hypertension-Induced Cardiac Hypertrophy and Fibrosis.
Watson CJ; Horgan S; Neary R; Glezeva N; Tea I; Corrigan N; McDonald K; Ledwidge M; Baugh J
J Cardiovasc Pharmacol Ther; 2016 Jan; 21(1):127-37. PubMed ID: 26130616
[TBL] [Abstract][Full Text] [Related]
36. Super-enhancers define a proliferative PGC-1α-expressing melanoma subgroup sensitive to BET inhibition.
Gelato KA; Schöckel L; Klingbeil O; Rückert T; Lesche R; Toedling J; Kalfon E; Héroult M; Lejeune P; Mönning U; Fernández-Montalván AE; Bäurle S; Siegel S; Haendler B
Oncogene; 2018 Jan; 37(4):512-521. PubMed ID: 28991225
[TBL] [Abstract][Full Text] [Related]
37. Selective inhibition of BET bromodomain epigenetic signalling interferes with the bone-associated tumour vicious cycle.
Lamoureux F; Baud'huin M; Rodriguez Calleja L; Jacques C; Berreur M; Rédini F; Lecanda F; Bradner JE; Heymann D; Ory B
Nat Commun; 2014 Mar; 5():3511. PubMed ID: 24646477
[TBL] [Abstract][Full Text] [Related]
38. JQ1, an inhibitor of the epigenetic reader BRD4, suppresses the bidirectional MYC-AP4 axis via multiple mechanisms.
Choi SK; Hong SH; Kim HS; Shin CY; Nam SW; Choi WS; Han JW; You JS
Oncol Rep; 2016 Feb; 35(2):1186-94. PubMed ID: 26573731
[TBL] [Abstract][Full Text] [Related]
39. Profiling the regulatory interplay of BET bromodomains and Sirtuins in cancer cell lines.
Järvenpää J; Rahnasto-Rilla M; Lahtela-Kakkonen M; Küblbeck J
Biomed Pharmacother; 2022 Mar; 147():112652. PubMed ID: 35065514
[TBL] [Abstract][Full Text] [Related]
40. Enhancer Remodeling during Adaptive Bypass to MEK Inhibition Is Attenuated by Pharmacologic Targeting of the P-TEFb Complex.
Zawistowski JS; Bevill SM; Goulet DR; Stuhlmiller TJ; Beltran AS; Olivares-Quintero JF; Singh D; Sciaky N; Parker JS; Rashid NU; Chen X; Duncan JS; Whittle MC; Angus SP; Velarde SH; Golitz BT; He X; Santos C; Darr DB; Gallagher K; Graves LM; Perou CM; Carey LA; Earp HS; Johnson GL
Cancer Discov; 2017 Mar; 7(3):302-321. PubMed ID: 28108460
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
